Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Follow-up of Fingolimod Phase II Study Patients (ACROSS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02307838
Recruitment Status : Completed
First Posted : December 4, 2014
Results First Posted : March 23, 2017
Last Update Posted : March 23, 2017
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This study collected follow-up data on approximately 90% of participants who were randomized and received one dose of study drug in FTY720D2201 (D2201). No study drug was given or required. Participants were required to be assessed at one or two visits, preferably at the original study site, but the option to be interviewed via phone or seen at home was provided. Information was gathered also on deceased participants. Assessments were performed only once within an 8 week period and included medical history, Multiple Sclerosis (MS) and Multiple Sclerosis Disease Modifying Therapy (MS DMT) history, Expanded Disability Status Scale (EDSS), Magnetic Resonance Imaging (MRI), and Multiple Sclerosis Functional Composite (MSFC).

Condition or disease Intervention/treatment Phase
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis Other: Assessments arm Phase 4

Detailed Description:
This was a multicenter follow-up study of patients originally enrolled in the Phase 2 D2201 study. Patients did not receive any protocol specified treatment. The original D2201 study sites who agreed to participate in this study were required to locate their patients who were randomized in Study D2201 and asked them to return for a 10-year assessment, regardless of their current treatment status. Locating the patient may have required the use of search and advertising strategies to find those patients currently lost to follow-up, in accordance with local privacy legislation. Patients currently being followed within Study FTY720D2399 (NCT01201356) were asked to participate in Study FTY720D2201E2 and if patients gave consent, were enrolled concurrently in both studies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 177 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Long-term Follow-up at 10 Years of Patients Enrolled in the Fingolimod Phase II Program in Relapsing Multiple Sclerosis (MS)
Study Start Date : June 2014
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Phase 2 CFTY720D2201 (NCT02307838) participants
CFTY720D2201E2 participants did not receive any protocol specified treatment. The original D2201 study sites, who agreed to participate in this study, were required to locate their participants who were randomized in D2201 and asked them to return for a 10 year assessment, regardless of current treatment status.
Other: Assessments arm
Protocol required assessments not provided in standard of care




Primary Outcome Measures :
  1. Change From Baseline (BL) in Expanded Disability Status Scale (EDSS) [ Time Frame: baseline from core study (CFTY720D2201 (NCT00333138)), 10 years ]
    EDSS is a scale for assessing neurologic impairment in MS. It consists of eight functional systems (FS) which are used to derive the EDSS steps (score) ranging from 0 (normal) to 10 (death due to MS). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the participant's score is determined between 0 to 10. A negative change from baseline indicates improvement.


Secondary Outcome Measures :
  1. Number of Participants With Disability Progression [ Time Frame: 10 Years ]
    Disability progression is defined as: 1.5-point increase from baseline in participants with baseline EDSS score = 0.0; OR 1-point increase in EDSS from baseline in participants with baseline EDSS score of 1.0 to 5.0 inclusive; OR 0.5-point increase in EDSS from baseline in participants with baseline EDSS score >5.0.

  2. Number of Participants With EDSS <4 or <6 [ Time Frame: 10 years ]
    EDSS is a scale for assessing neurologic impairment in MS. It consists of eight functional systems (FS) which are used to derive the EDSS steps (score) ranging from 0 (normal) to 10 (death due to MS). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the participant's score is determined between 0 to 10. A positive change from baseline indicates improvement.

  3. Number of Participants Not Using a Wheelchair or Being Bedridden [ Time Frame: 10 years ]
    The number of participants not using a wheelchair or being bedridden was assessed.

  4. Number of Participants Classified as Secondary Progressive MS (SPMS) [ Time Frame: 10 years ]
    SPMS follows an initial relapsing-remitting course. Most people who are diagnosed with relapsing-remitting multiple sclerosis (RRMS) will eventually transition to a secondary progressive course in which there is a progressive worsening of neurologic function (accumulation of disability) over time. Participants who were classified as SPMS were assessed.

  5. Percentage of Participants With First Use of an Ambulatory Device [ Time Frame: 10 years ]
    First use of an ambulatory device was considered from EDSS 6.0 for participants having started FTY720D2201 (NCT00333138) with an EDSS score below 6.0.

  6. Percentage of Participants With First Use of a Wheelchair [ Time Frame: 10 years ]
    First use of a wheelchair was considered from EDSS 7.0 for participants having started FTY720D2201 (NCT00333138) with an EDSS score below 7.0.

  7. Change From Baseline in Multiple Sclerosis Fuctional Composite (MSFC) Component: Nine Hole Peg Test (9-HPT) [ Time Frame: baseline from core study, CFTY720D2201 (NCT00333138), 10 years ]
    The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Both the dominant and non-dominant hands are tested twice (two consecutive trials of the dominant hand, followed immediately by two consecutive trials of the non-dominant hand). The time limit per trial is 300 seconds. The right and left hand scores were the time in seconds it took to insert and remove 9 pegs ((the average scores from the four trials on the 9-HPT (the two trials for each hand are averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals are averaged)). A negative change from baseline indicates improvement.

  8. Change From Baseline in MSFC Component: Paced Auditory Serial Addition Test (PASAT) Score [ Time Frame: baseline from core study (CFTY720D2201 (NCT00333138)), 10 years ]
    The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. The PASAT is the last measure administered at each visit. It is presented on audio compact disc (CD) to control the rate of stimulus presentation. Single digits are presented every 3 seconds and the patient must add each new digit to the one immediately prior to it. The test result is the number of correct sums given (out of 60 possible). A positive change from baseline indicates improvement.

  9. Change From Baseline in MSFC Component: Timed 25-foot Walk Test Score [ Time Frame: baseline from core study (CFTY720D2201 (NCT00333138)), 10 years ]
    The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The patient is directed to one end of a clearly marked 25-foot (7.62 m) course and is instructed to walk 25 feet (7.62 meter) as quickly as possible, but safely. The task is immediately administered again by having the patient walk back the same distance. Patients may use assistive devices when doing this task. The test scores were the time in seconds it took to walk the 25 feet. A negative change from baseline indicates improvement.

  10. Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Z Score [ Time Frame: baseline from core study (CFTY720D2201 (NCT00333138)), 10 years ]
    MSFC is a composite measure encompassing information from the nine-hole peg test (arm dimension), timed 25 foot walk (leg dimension) and PASAT. The MSFC composite Z score was calculated as follows: (1) the average scores from the four trials on the 9-HPT (the two trials for each hand were averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals were averaged); (2) the average scores of two 25-Foot Timed Walk trials; (3) the number correct from the PASAT-3. The MSFC is based on the concept that scores for these three dimensions—arm, leg, and cognitive function are combined to create a single score (the MSFC) that can be used to detect change over time in a group of multiple sclerosis patients. This was done by creating Z-scores for each component of the MSFC, and averaging them to create an overall composite Z score.

  11. Total Volume in T2 Lesion [ Time Frame: 10 years ]
    Total volume in T2 lesion was assessed by magnetic resonance imaging (MRI).

  12. Change From Baseline in Total Volume of T2 Lesion [ Time Frame: baseline from core study (CFTY720D2201 (NCT00333138)), 10 years ]
    Total volume in T2 lesion was assessed by magnetic resonance imaging (MRI). A negative change from baseline indicates improvement.

  13. Third Ventricle Diameter [ Time Frame: 10 years ]
    Third ventricle diameter was assessed by MRI.

  14. Change From Baseline in Third Ventricle Diameter [ Time Frame: baseline from core study (CFTY720D2201 (NCT00333138)), 10 years ]
    Third ventricle diameter was assessed by MRI. A negative change from baseline indicates improvement.

  15. Percentage Brain Volume Change (PBVC) [ Time Frame: baseline from core study (CFTY720D2201 (NCT00333138)), 10 years ]
    PVBC was assessed by MRI. A negative change from baseline indicates improvement.

  16. Correlation Coeffcients Between FTY Treatment Duration and Disability Progression Parameters [ Time Frame: 10 years ]
    The correlation between FTY treatment duration and disability progression outcomes was assessed. The number presented in the table is the Pearson correlation coefficient, r.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent must be obtained before any assessment is performed.
  • Randomized in study FTY720D2201 and received at least one dose of study drug.

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02307838


Locations
Layout table for location information
Canada, Ontario
Novartis Investigative Site
Ottawa, Ontario, Canada, K1H 8L6
Novartis Investigative Site
Toronto, Ontario, Canada, M5B 1N9
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H2L 4M1
Novartis Investigative Site
Montreal, Quebec, Canada, H3A 2B4
Denmark
Novartis Investigative Site
Copenhagen, Denmark, DK-2100
Novartis Investigative Site
Glostrup, Denmark, DK-2600
France
Novartis Investigative Site
Lille, France, 59037
Novartis Investigative Site
Marseille, France, 13385
Germany
Novartis Investigative Site
Würzburg, Germany, 97080
Italy
Novartis Investigative Site
Genova, GE, Italy, 16132
Novartis Investigative Site
Milano, MI, Italy, 20132
Novartis Investigative Site
Roma, RM, Italy, 00189
Novartis Investigative Site
Gallarate, VA, Italy, 21013
Poland
Novartis Investigative Site
Warszawa, Poland, 02-097
Novartis Investigative Site
Warszawa, Poland, 02-957
Portugal
Novartis Investigative Site
Coimbra, Portugal, 3000-075
Novartis Investigative Site
Lisboa, Portugal, 1150-314
Spain
Novartis Investigative Site
Malaga, Andalucia, Spain, 29010
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41009
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
L'Hospitalet de Llobregat, Catalunya, Spain, 08907
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46026
Novartis Investigative Site
Madrid, Spain, 28040
Switzerland
Novartis Investigative Site
Basel, Switzerland, 4031
Novartis Investigative Site
Zuerich, Switzerland, 8091
United Kingdom
Novartis Investigative Site
Newcastle Upon Tyne, United Kingdom, NE1 4LP
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02307838     History of Changes
Other Study ID Numbers: CFTY720D2201E2
First Posted: December 4, 2014    Key Record Dates
Results First Posted: March 23, 2017
Last Update Posted: March 23, 2017
Last Verified: February 2017

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Multiple Sclerosis, MS, RRMS, relapsing forms of multiple sclerosis, fingolimod, FTY720, Gilenya

Additional relevant MeSH terms:
Layout table for MeSH terms
Sclerosis
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Fingolimod Hydrochloride
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs